
FDA verdict on Biogen’s Alzheimer’s drug likely to be a ‘political decision,’ analyst says
Federal regulators may buckle to public and political pressure to approve Biogen’s experimental Alzheimer’s drug, aducanumab, Jefferies’ Michael Yee told CNBC […]
0